Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts [0.03%]
基于患者源性肿瘤异种移植模型的药物反应研究设计优化
Jessica Weiss,Nhu-An Pham,Melania Pintilie et al.
Jessica Weiss et al.
Patient-derived tumor xenograft (PDX) models were used to evaluate the effectiveness of preclinical anticancer agents. A design using 1 mouse per patient per drug (1 × 1 × 1) was considered practical for large-scale drug efficacy studies....
A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy [0.03%]
用于预测抗PD1免疫治疗反应的随机森林基因组分类器
Emma Bigelow,Suchi Saria,Brian Piening et al.
Emma Bigelow et al.
Tumor mutational burden (TMB), a surrogate for tumor neoepitope burden, is used as a pan-tumor biomarker to identify patients who may benefit from anti-program cell death 1 (PD1) immunotherapy, but it is an imperfect biomarker. Multiple add...
A transcriptome-Based Deep Neural Network Classifier for Identifying the Site of Origin in Mucinous Cancer [0.03%]
基于转录组的深度神经网络分类器在粘液癌中确定原发部位识别
Taejin Ahn,Kidong Kim,Hyojin Kim et al.
Taejin Ahn et al.
Purpose: There is a lack of tools for identifying the site of origin in mucinous cancer. This study aimed to evaluate the performance of a transcriptome-based classifier for identifying the site of origin in mucinous canc...
Innovative Approach for a Typology of Treatment Sequences in Early Stage HER2 Positive Breast Cancer Patients Treated With Trastuzumab in the French National Hospital Database [0.03%]
基于法国国家医院数据库的HER2阳性乳腺癌患者曲妥珠单抗治疗早期阶段的治疗序列类型的新方法
Olivier Tredan,Marie Laurent,Melina Gilberg et al.
Olivier Tredan et al.
Background: Our objective was to describe the hospital-based systemic treatment sequences in early stage HER2+ breast cancer patients treated with trastuzumab in France in 2016. ...
Contextual Validation of the Prediction of Postoperative Complications of Colorectal Surgery by the " ACS NSQIP ® Risk Calculator" in a Tunisian Center [0.03%]
"ACS NSQIP®风险计算器"在突尼斯中心预测结直肠手术后并发症的临床验证研究
Mehdi Ben Abdelkrim,Mohamed Amine Elghali,Amany Moussa et al.
Mehdi Ben Abdelkrim et al.
Context: Models for predicting individual risks of surgical complications are advantageous for operative decision making and the nature of postoperative management procedures. ...
Methylation of CpG Sites as Biomarkers Predictive of Drug-Specific Patient Survival in Cancer [0.03%]
CpG位点的甲基化作为预测癌症患者药物特异性生存率的生物标志物
Bridget Neary,Shuting Lin,Peng Qiu
Bridget Neary
Background: Though the development of targeted cancer drugs continues to accelerate, doctors still lack reliable methods for predicting patient response to standard-of-care therapies for most cancers. DNA methylation has ...
Integrated Molecular Analysis Reveals 2 Distinct Subtypes of Pure Seminoma of the Testis [0.03%]
综合分子分析揭示了睾丸纯精原细胞瘤的两种不同的亚型
Kirill E Medvedev,Anna V Savelyeva,Kenneth S Chen et al.
Kirill E Medvedev et al.
Objective: Testicular germ cell tumors (TGCT) are the most common solid malignancy in adolescent and young men, with a rising incidence over the past 20 years. Overall, TGCTs are second in terms of the average life years ...
SurviveAI: Long Term Survival Prediction of Cancer Patients Based on Somatic RNA-Seq Expression [0.03%]
基于体细胞RNA测序表达的癌症患者长期生存预测：SurviveAI系统
Omri Nayshool,Nitzan Kol,Elisheva Javaski et al.
Omri Nayshool et al.
Motivation: Prediction of cancer outcome is a major challenge in oncology and is essential for treatment planning. Repositories such as The Cancer Genome Atlas (TCGA) contain vast amounts of data for many types of cancers...
Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment [0.03%]
用于个性化乳腺癌治疗的表皮生长因子受体（EGFR），人表皮生长因子受体2（HER2），雌激素受体（ER）和磷脂酰肌醇3-激酶α（PI3Kα）的 promising 抑制剂的发现
Precious A Akinnusi,Samuel O Olubode,Ayomide O Adebesin et al.
Precious A Akinnusi et al.
Despite the rapid developments and advancements to improve treatments, Breast cancer remains one of the deadliest health challenges and the most frequently diagnosed tumor. One of the major problems with treatment is the unique difference t...
Transcription Elongation Factor A (SII)-Like (TCEAL) Gene Family Member-TCEAL2: A Novel Prognostic Marker in Pan-Cancer [0.03%]
泛癌中新的预后标志物TCEAL2：转录延长因子A（SII）家族成员
Yu Sun,Jun Zhao
Yu Sun
Background: Cancer is the leading cause of death in the world. The mechanism is not fully elucidated and the therapeutic effect is also unsatisfactory. In our study, we aim to find new target gene in pan-cancer. ...